May 9 |
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
|
May 7 |
Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
May 6 |
Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...
|
May 6 |
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
|
May 6 |
Foghorn Therapeutics GAAP EPS of -$0.59, revenue of $5.1M
|
May 6 |
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
|
Apr 16 |
Foghorn Therapeutics appoints Kristian Humer as chief financial officer
|
Apr 16 |
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
|
Apr 9 |
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
|
Apr 9 |
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
|